Search tips
Search criteria 


Logo of ijpsychHomeCurrent issueInstructionsSubmit article
Indian J Psychiatry. 2002 Oct-Dec; 44(4): 365–371.
PMCID: PMC2955309



Centbutindole is a new antipsychotic agent related to butyrophenone group. The drug is dopamine antagonist but it also blocks 5HT2 receptors. Clinically the drug has passed through phase I, II & III clinical trials successfully and it has shown effective antipsychotic activity in schizophrenic patients. In the present study the drug was compared with risperidone in a double blind manner for a period of 8 weeks to assess the efficacy in schizophrenic patients. Patients of schizophrenia evaluated on PANSS, CGI & UKU side effect rating scale weekly Out of 44 patients included in study, 38 completed the trial. The intergroup comparison of two drugs showed that centbudindole and risperidone have similar onset of antipsychotic action as both the drugs showed significant decrease in the total PANSS score as well as positive syndrome score, negative syndrome score and general psychopathology score from 2nd week onwards. The scores in both the groups showed a steady and significant decline from 2nd week to 8th week of study. The present study showed that centbutindole has similar improvement on clinical global impression with risperidone. The side effect profile was similar in the two drugs except dystonia (5 patients in centbutindole vs 1 patient in risperidone group). The findings of present study shows that Centbutindole could be used as a promising new drug for treatment of schizophrenia in place of a typical antipsychotics as it has shown improvement on negative symptoms similar to risperidone.

Keywords: Centbutindole, Risperidone, Atypical Antipsychotics and Extrapyramidal symptoms

Full Text

The Full Text of this article is available as a PDF (269K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan GW, Labelle A, Beauclair L, Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993 Feb;13(1):25–40. [PubMed]
  • Baird JK, Lacy MD, Basri H, Barcus MJ, Maguire JD, Bangs MJ, Gramzinski R, Sismadi P, Krisin, Ling J, et al. Randomized, parallel placebo-controlled trial of primaquine for malaria prophylaxis in Papua, Indonesia. Clin Infect Dis. 2001 Dec 15;33(12):1990–1997. [PubMed]
  • Gulati A, Bhargava HN. Effect of melanotropin release inhibiting factor on changes by haloperidol and centbutindole in cerebral cortical 5-hydroxytryptamine receptors. Pharmacology. 1990;41(2):98–106. [PubMed]
  • Gulati A, Srimal RC, Dhawan BN. Differential alteration in striatal dopaminergic and cortical serotonergic receptors induced by repeated administration of haloperidol or centbutindole in rats. Pharmacology. 1988;36(6):396–404. [PubMed]
  • Jalenques I. Approche psychopharmacologique des symptômes négatifs dans les schizophrénies. Encephale. 1995 Jun;21(SPEC):35–40. [PubMed]
  • Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane JM. Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry. 1994 Dec;151(12):1744–1752. [PubMed]
  • McEvoy JP. Efficacy of risperidone on positive features of schizophrenia. J Clin Psychiatry. 1994 May;55 (Suppl):18–21. [PubMed]
  • Marder SR. Clinical experience with risperidone. J Clin Psychiatry. 1996;57 (Suppl 9):57–61. [PubMed]
  • Saxena AK, Jain PC, Anand N. Agents acting on the central nervous system. 15. 2-Substituted 1,2,3,4,6,7,12,12a-octahydropyrazino(2',1':6,1)pyrido(3,4-b)indoles. A new class of central nervous system depressants. J Med Chem. 1973 May;16(5):560–564. [PubMed]

Articles from Indian Journal of Psychiatry are provided here courtesy of Wolters Kluwer -- Medknow Publications